Home / Stocks / Venus Remedies Limited
VENUSREM

Venus Remedies Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,501.6

Change

+46.6 (3.2%)

Open

₹1,451.0

Prev. Close

₹1,455.0

Day High

₹1,527.7

Day Low

₹1,431.0

Volume Analysis

Traded

42,678

Delivered

23,091

Delivery %

54.11%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (21.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (57.0%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,639.24 ₹1,583.47 ₹1,542.54 ₹1,486.77 ₹1,445.84 ₹1,390.07 ₹1,349.14
Fibonacci ₹1,583.47 ₹1,546.53 ₹1,523.71 ₹1,486.77 ₹1,449.83 ₹1,427.01 ₹1,390.07
Camarilla ₹1,528.19 ₹1,519.33 ₹1,510.46 ₹1,486.77 ₹1,492.74 ₹1,483.87 ₹1,475.01

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+97.45%

1 Week

+3.95%

1 Month

-0.81%

3 Months

-13.61%

6 Months

+38.77%

1 Year

+117.91%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹954.9

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

15.79%

Net margin 14.58% × asset turnover 0.91x × equity multiplier 1.19x

Company Overview

Sector

Healthcare

Market Cap

₹2,002 Cr

P/E (TTM)

16.4

ROE

15.6%

Book Value

₹527.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Venus Remedies Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Liquidity (49/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (21.0%). Strong 3-year EPS growth (57.0%).

TopFund Score — Fundamentals Quality

70/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

59

Valuation

52

Cash Flow

80

Corporate Governance

78

Momentum

63

Institutional Ownership

53

Business Quality

80

Risk & Volatility

65

Liquidity

49

From Screener.in

  • +Company is almost debt free.
  • +Company has delivered good profit growth of 20.0% CAGR over last 5 years
  • +Company's working capital requirements have reduced from 88.6 days to 61.9 days
  • −Stock is trading at 2.84 times its book value
  • −The company has delivered a poor sales growth of 7.09% over past five years.
  • −Company has a low return on equity of 9.53% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 168 143 195 109 170 177 195 137 193 180 259 179 219
Expenses + 150 131 176 97 163 158 166 122 162 143 196 145 176
Operating Profit 18 12 19 11 8 18 29 15 31 38 63 34 42
OPM % 11.0% 8.0% 10.0% 10.0% 4.5% 10.0% 15.0% 11.0% 16.0% 21.0% 24.0% 19.0% 19.0%
Other Income + 3 2 4 2 8 12 7 3 2 3 5 3 1
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 6 7 6 6 6 5 5 6 6 7 7 7 10
Profit before tax 14 8 17 7 9 25 31 13 26 33 62 30 33
Tax % 31.0% 12.0% 40.0% 82.0% 61.0% 21.0% 32.0% 24.0% 24.0% 24.0% 23.0% 24.0% 23.0%
Net Profit + 10 7 11 1 4 20 21 10 20 26 48 23 26
EPS in Rs 7 5 8 1 3 15 16 7 15 19 36 17 19
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 20 23 25 14 1 23 0 26 13 2 33 30 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 455 407 400 372 322 335 544 597 552 596 645 766 837
Expenses + 366 326 349 333 289 295 490 535 492 537 577 619 660
Operating Profit 89 81 51 39 33 41 54 62 60 60 69 147 178
OPM % 20.0% 20.0% 13.0% 11.0% 10.0% 12.0% 10.0% 10.0% 11.0% 10.0% 11.0% 19.0% 21.0%
Other Income + 1 2 2 2 -3 -4 43 8 10 12 26 13 11
Interest 41 38 34 35 25 13 13 0 0 0 0 0 0
Depreciation 46 42 40 34 34 32 35 34 32 26 23 26 30
Profit before tax 3 4 -22 -28 -30 -8 49 36 38 45 72 134 159
Tax % -95.0% 52.0% -21.0% 11.0% -4.0% 24.0% -27.0% -12.0% 30.0% 36.0% 37.0% 23.0% —
Net Profit + 5 2 -17 -31 -29 -10 62 41 27 28 45 103 122
EPS in Rs 5 1 -14 -25 -23 -8 50 30 20 21 34 77 91
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 13.0% —
Sales growth -14 -11 -2 -7 -14 4 62 10 -8 8 8 19 19

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 445 426 376 350 320 311 388 427 447 474 548 650 691
Borrowings + 321 335 312 307 298 220 51 43 42 41 2 12 12
Other Liabilities + 64 70 65 82 102 100 104 97 98 98 153 178 123
Total Liabilities 841 843 765 751 733 644 556 580 601 627 716 854 840
Fixed Assets + 444 452 406 389 364 289 262 241 216 219 229 232 217
CWIP 78 80 66 65 65 25 25 25 26 21 26 51 75
Investments 0 0 0 0 0 0 0 0 20 19 84 238 240
Other Assets + 319 310 293 297 304 330 269 314 339 368 376 333 307
Total Assets 841 843 765 751 733 644 556 580 601 627 716 854 840
Equity Capital 11 11 12 12 12 12 12 13 13 13 13 13 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 68 47 59 31 45 78 132 41 37 37 86 156
Cash from Investing Activity + -67 3 -18 8 -11 -5 57 -17 -58 -8 -77 -185
Cash from Financing Activity + -1 -46 -44 -39 -35 -73 -162 -9 -1 -1 -1 -3
Net Cash Flow -1 3 -4 0 -1 0 27 14 -22 28 9 -32
Free Cash Flow 59 46 41 19 35 70 132 41 29 24 69 118
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 76 58 116 79 139 190 245 66 61 89 148 129

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 41.76% → 41.76%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 56.65% 56.76% 57.17% 57.06% 57.13% 56.9% 55.89% 55.62% 54.95% 54.24% 54.44% 54.37%
Promoters 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76%
FII 1.59% 1.48% 1.06% 1.18% 1.11% 1.34% 2.25% 1.86% 2.25% 2.8% 2.92% 3.14%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.11% 0.75% 1.03% 1.2% 0.89% 0.74%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Venus Remedies Limited (this stock) 2,002 16.4 2.84 15.6%
Hester Biosciences Ltd 1,992 33.9 4.26 15.9%
Beta Drugs Limited 1,990 38.3 4.54 18.8%
Windlas Biotech Limited 2,067 31.1 3.64 12.2%
Indoco Remedies Ltd. 2,079 — 2.03 -9.36%
Syncom Formu (i) Ltd 1,907 20.0 4.06 17.6%
Panacea Biotec Ltd 2,171 — 2.6 -2.42%

Which Mutual Funds Hold Venus Remedies Limited?

Frequently Asked Questions about Venus Remedies Limited

Community Sentiment

What are other investors saying about Venus Remedies Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.